Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Director | January 25, 2018 | January 26, 2018 |
| Seaport Therapeutics, Inc.SPTX · Entity 4799 | Director · Chief Executive Officer | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date January 25, 2018 · Filed January 26, 2018
This filing explicitly reported no securities owned.
Seaport Therapeutics, Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 271,813 |
Reported balance
After 2026-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 271,813 · Balance 271,813 F1: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 1,486,786 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 1,486,786 · Balance 1,486,786 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 22:18 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | GrantStock Option (Right to Buy) · Derivative | 1,486,786 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204507 · ownership.xml · derivative · entry 2 Zohar Daphne · CIK 0001727388 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,486,786 Underlying: Common Stock · 1,486,786 shares Expires 2036-04-29 Read SEC document |
| April 30, 2026 Filed May 4, 2026 22:18 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | GrantStock Option (Right to Buy) · Derivative | 271,813 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204507 · ownership.xml · derivative · entry 1 Zohar Daphne · CIK 0001727388 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,813 Underlying: Common Stock · 271,813 shares Expires 2036-04-29 F1 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.